| Study |
Reference |
|
Colvin, 2010
|
Colvin Linking a pharmaceutical claims database with a birth defects registry to investigate birth defect rates of suspected teratogens. Pharmacoepidemiol Drug Saf 2010; 19:1137-50
|
|
Fragoso a (control exposed to Glatiramer), 2013
|
Fragoso Long-term effects of exposure to disease-modifying drugs in the offspring of mothers with multiple sclerosis: a retrospective chart review. CNS Drugs 2013; 27:955-61
|
|
Fragoso a (control unexposed, sick), 2013
|
Fragoso Long-term effects of exposure to disease-modifying drugs in the offspring of mothers with multiple sclerosis: a retrospective chart review. CNS Drugs 2013; 27:955-61
|
|
Nguyen (control exposed to Glatiramer), 2019
|
Nguyen Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. Mult Scler Relat Disord 2019; 28:235-243
|
|
Nguyen (control unexposed, sick), 2019
|
Nguyen Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. Mult Scler Relat Disord 2019; 28:235-243
|
|
Weber-Schoendorfer (control exposed to Glatiramer), 2009
|
Weber-Schoendorfer Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult. Scler. 2009; 15:1037-42
|
|
Weber-Schoendorfer (control unexposed, disease free), 2009
|
Weber-Schoendorfer Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult. Scler. 2009; 15:1037-42
|
|
Weber-Schoendorfer (control unexposed, sick), 2009
|
Weber-Schoendorfer Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult. Scler. 2009; 15:1037-42
|
